EUTECNIQAtlas

Every page of EUTECNIQ on one mapArrow keys move through results · Enter opens · Esc closes

Supplements A–Z Amino acid and protein Sources: 5

Lactotripeptides (IPP and VPP)

Also called: isoleucine-proline-proline, valine-proline-proline, IPP, VPP, casein-derived tripeptides, milk tripeptides

Lactotripeptides are the tripeptides isoleucine-proline-proline (IPP) and valine-proline-proline (VPP), which can be released from milk β-casein and κ-casein. They are made by fermentation with proteolytic starter cultures, by enzymatic hydrolysis or by chemical synthesis.

Category
Amino acid and protein
Forms
IPP and VPP in tablets or capsules, or added to milk drinks, yogurt drinks or fruit and vegetable juices; made with Lactobacillus helveticus or Saccharomyces cerevisiae fermentation or Aspergillus oryzae enzyme hydrolysis of casein
Strongest evidence
B Some positive trials
Reviewed
2026-10-30

Class 1 Well studied in people. A 2015 meta-analysis pooled 30 RCTs (33 data sets) of casein-derived lactotripeptides on blood pressure in adults; 10 trials used tablets or capsules, and the rest milk drinks, fruit and vegetable juices or yoghurt drinks. [1]

Fact-checked 2026-10-30 · How this guide is made

Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.

Evidence

What research has studied

Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.

3 topics studied1 body area · strongest grade B

A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials

From the table below Each topic in the table is placed on the part of the body it names, colored by its strongest grade. Tap an area, or open a line in the list, to see its topics. The map shows what was studied, not what Lactotripeptides (IPP and VPP) does: a C or X area is not evidence of benefit. All 1,071 findings on one body map.
Topics studied for Lactotripeptides (IPP and VPP), evidence grade and finding
Topic studiedGradeWhat the evidence shows
Blood pressure in adultsBA 2015 meta-analysis of 30 RCTs found systolic -2.95 and diastolic -1.51 mmHg; 24-hour ambulatory pressure did not change significantly, and publication bias and small-study effects weakened the result. [1]
Blood pressure in European adultsBA 2013 meta-analysis of 14 trials (15 data sets, 1,306 subjects) found systolic -1.28 mmHg and diastolic -0.59 mmHg versus placebo, with no evidence of publication bias. [2]
Systolic blood pressure in Japanese adultsBA 2015 meta-analysis of 18 studies (1,194 subjects) found systolic -5.63 mmHg versus placebo, larger in hypertensive subjects; the authors disclosed industry payment for performing the review. [3]

Main constituents: Isoleucine-proline-proline (IPP) and valine-proline-proline (VPP) [1]

Amounts

Amounts studied and limits

Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.

  • Trials in a 2015 meta-analysis used an average of 10.5 mg/day of lactotripeptides (5.2 mg/day IPP and 5.3 mg/day VPP) for 4 to 21 weeks (average 7.8 weeks). [1]

No official upper intake level has been set.

Safety

Safety and side effects

  • Liver (NIH LiverTox)
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Pregnancy and breastfeeding
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Interactions with medicines
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Cancer evaluations (IARC, NTP)
    None found

    No IARC or NTP evaluation was found in the lists checked.

    Details and sources
  • FDA new dietary ingredient notifications
    None on FDA's list

    FDA does not approve dietary supplements. Each entry is one party's filing.

    Details and sources
  • Dose in official monographs
    None found

    No published information found in the sources checked.

    Details and sources
  • A 2015 meta-analysis of 30 RCTs states that the adverse effects of antihypertensive drugs have not been reported for lactotripeptide use; three included trials had the safety of excessive intake as their primary outcome. [1]
Regulation

Regulatory status

  • EU: EFSA's NDA Panel (2012) concluded that "a cause and effect relationship has not been established between the consumption of IPP and VPP and maintenance of normal blood pressure"; 15 of the human intervention studies provided, seven of them adequately powered, "did not observe an effect". [4]
  • US: under DSHEA, FDA does not have the authority to approve dietary supplements before they are marketed; firms are responsible for ensuring their products are not adulterated or misbranded. [5]
Profile

Safety, quality and supply profile

Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-30). If our sources do not answer a question, we say so.

Compounds responsible

Compounds the sources name as the main or characteristic actives.

  • Isoleucine-proline-proline (IPP) and valine-proline-proline (VPP), released from β-casein and κ-casein Amino acids, amines and peptides (tripeptides) [P1]

US status

What FDA's published records show. FDA does not approve dietary supplements.

  • No NDI notification naming lactotripeptides (isoleucine-proline-proline or valine-proline-proline) was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-30). FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [P2]

Cancer evaluations (IARC and NTP)

Evaluations name the exact material tested, which may differ from a supplement.

  • No IARC or NTP carcinogenicity evaluation of lactotripeptides (IPP, VPP) was found (IARC Monographs list of classifications, Volumes 1–142, and NTP technical reports checked 2026-10-30). [P3]
  • The NTP Technical Reports index (TR-001 to TR-606) lists no study of lactotripeptides (IPP, VPP) (checked 2026-10-30). [P4]

Liver (NIH LiverTox)

  • No published information found in the sources checked.

Interactions with medicines

  • No published information found in the sources checked.

Alcohol

  • No published information found in the sources checked.

Interactions with other herbs and supplements

  • No published information found in the sources checked.

Adulteration and substitution

  • No published information found in the sources checked.

What a certificate of analysis should cover

Tests a quality specification for this material would include, with the reason for each.

  • Identity: at least one appropriate test or examination to verify the identity of each component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)) — General Part 111 requirement for every dietary ingredient; FDA may exempt a firm only by granting a petition under 111.75(a)(1)(ii). [P5]

Supply and conservation

  • No published information found in the sources checked.

Absorption in people

  • No published information found in the sources checked.

Formulations studied to change absorption

Human data only.

  • No published information found in the sources checked.

Dose in official monographs

As the monograph states it, for its jurisdiction; not personal advice.

  • No published information found in the sources checked.

Pregnancy and breastfeeding

  • No published information found in the sources checked.

Sources for this profile

  1. Fekete ÁA, Givens DI, Lovegrove JA. Casein-derived lactotripeptides reduce systolic and diastolic blood pressure in a meta-analysis of randomised clinical trials. Nutrients 2015;7(1):659-681 (PMID 25608938; full text PMC4303860), 2015-01-20. pmc.ncbi.nlm.nih.gov
  2. FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
  3. IARC Monographs. List of Classifications: agents classified by the IARC Monographs, Volumes 1–142, 2026-10-30. monographs.iarc.who.int
  4. National Toxicology Program. Technical Reports (TR series index, TR-001 to TR-606), 2026-10-30. ntp.niehs.nih.gov
  5. eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/29/2026), 2026-10-29. ecfr.gov
Sources

Sources

  1. Fekete ÁA, Givens DI, Lovegrove JA. Casein-derived lactotripeptides reduce systolic and diastolic blood pressure in a meta-analysis of randomised clinical trials. Nutrients 2015;7(1):659-681 (PMID 25608938; full text PMC4303860), 2015-01-20. pmc.ncbi.nlm.nih.gov
  2. Cicero AF, et al. Do the lactotripeptides isoleucine-proline-proline and valine-proline-proline reduce systolic blood pressure in European subjects? A meta-analysis of randomized controlled trials. Am J Hypertens 2013;26(3):442-449 (PMID 23382495), 2013-01-07. pubmed.ncbi.nlm.nih.gov
  3. Chanson-Rolle A, et al. Influence of the Lactotripeptides Isoleucine-Proline-Proline and Valine-Proline-Proline on Systolic Blood Pressure in Japanese Subjects: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS One 2015;10(11):e0142235 (PMID 26536628), 2015-11-04. pubmed.ncbi.nlm.nih.gov
  4. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on the substantiation of health claims related to isoleucine-proline-proline (IPP) and valine-proline-proline (VPP) and maintenance of normal blood pressure (ID 661, 1831, 1832, 2891, further assessment) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2012;10(6):2715 (abstract read in the OpenAlex record; the EFSA, Wiley and doi.org pages returned access errors on 2026-10-30), 2012-06. api.openalex.org
  5. U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
A
Consistent results from several randomized trials or a systematic review of them
B
Some positive randomized trials, but small, short, few or inconsistent
C
Limited human evidence: single small trials, observational data or mixed results
D
Laboratory or animal evidence only; not shown in people
X
Well-designed human trials found no meaningful effect

More in amino acid and protein: 5-HTP (5-hydroxytryptophan) · Beta-alanine · BPC-157 · Branched-chain amino acids (BCAAs) · Carnosine (L-carnosine) · Collagen peptides · Creatine · Glutathione · All entries A–Z · How to judge a supplement

Health information notice

These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.

Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to check what you take?

Free tools built on published reference values, each with its sources and its limits. Your lists stay in your browser.